Experts warn of global gap in cancer treatment

The use of modern cancer drugs can vary by a factor of 10 between different developed countries, while millions in Africa lack access even to basic pain relief, experts said on Thursday.

Swedish researchers said there were "stark inequalities" in access to cancer medicine around the world, contributing to significant differences in patient survival.

The United States, France, Switzerland and Austria are the leaders in using new cancer drugs, while Britain, New Zealand, Poland, the Czech Republic and South Africa are laggards, according to an analysis of 67 medicines across 25 countries.
The biggest differences were seen in four new colorectal and lung cancer drugs - bevacizumab (Avastin); cetuximab (Erbitux); erlotinib (Tarceva); (Alimta); or pemetrexed (Alimta).

The use of Avastin for colorectal cancer in the United States, for example, was 10-times the European average, as was the use of Tarceva for lung cancer.

These drugs belong to a new class of targeted therapies that are helping patients live longer, with fewer side effects.

Dr. Bengt Jonsson, director of the Centre for Health Economics at the Stockholm School of Economics, said better access to such medicines was one reason why rates of survival from cancer were higher in France and Spain than in Britain.

"The introduction of new drugs explains part of the improvement. It doesn't explain everything, but it generally explains more than advances in radiotherapy and surgery," he told Reuters in a telephone interview.

His colleague Dr Nils Wilking, a clinical oncologist at the Karolinska Institute in Stockholm, said experience from the United States also showed that survival of cancer patients was related significantly to the introduction of new drugs.